---
id: epstein-barr-virus_105
category: organisms
tags: [EBV, infectious-mononucleosis, Burkitt-lymphoma, PTLD, Epstein-Barr-virus]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Epstein-Barr Virus (EBV)

**Q:** What are the clinical manifestations, diagnosis, and complications of EBV infection including infectious mononucleosis, EBV-associated malignancies (Burkitt lymphoma, PTLD), and treatment approaches?

**A:**

## OVERVIEW

**Organism:** Epstein-Barr virus (EBV) - Human herpesvirus 4 (HHV-4)

**Transmission:**
- **Saliva** ("kissing disease")
- **Blood transfusion, transplant** (rare)

**Epidemiology:**
- **>90% adults seropositive** worldwide
- **Primary infection:** Children (asymptomatic) OR adolescents/adults (infectious mononucleosis)

**Latency:** **B lymphocytes** (lifelong)

---

## 1. INFECTIOUS MONONUCLEOSIS (IM)

**Epidemiology:**
- **Adolescents and young adults** (peak age 15-24 years)
- **Clinical IM:** 30-50% of primary EBV infections in this age group

**Incubation:** **4-7 weeks**

---

### **Clinical Features:**

**Classic Triad (But Often Incomplete):**
1. **Fever** (>7-14 days)
2. **Pharyngitis** (severe, exudative - 50-90%)
3. **Lymphadenopathy** (cervical - posterior > anterior)

**Other Findings:**
- **Fatigue, malaise** (profound, can last weeks-months)
- **Splenomegaly** (50-60%)
- **Hepatomegaly** (10-15%), transaminitis (80%)
- **Palatal petechiae** (25-60%)
- **Rash:**
  - Maculopapular rash (5-15% - nonspecific)
  - **Ampicillin/amoxicillin rash** (80-100% if given antibiotics for misdiagnosed "strep throat")

**Key Point:** **Avoid ampicillin/amoxicillin** if infectious mononucleosis suspected (causes diffuse maculopapular rash)

---

**Diagnosis:**

| **Test** | **Timing** | **Sensitivity/Specificity** | **Notes** |
|----------|------------|----------------------------|-----------|
| **Heterophile antibody (Monospot)** | **After 1st week** | **Sens 70-90%**, Spec >95% | **Preferred initial test**<br>**False negatives:** Children <4 years, early infection (<1 week) |
| **EBV-specific antibodies** | Variable | High | Use if Monospot negative but high suspicion |
| **- VCA-IgM** | Acute infection | Positive in acute IM | Disappears after 4-6 weeks |
| **- VCA-IgG** | Acute → lifelong | Positive in acute + past infection | Persists for life |
| **- EBNA IgG** | Late (6-12 weeks) | Negative in acute IM | Appears 6-12 weeks, persists for life |

**Laboratory:**
- **Atypical lymphocytes** (>10% on peripheral smear - "Downey cells")
- **Lymphocytosis** (>50% lymphocytes, >10% atypical)
- **Transaminitis** (mild - ALT/AST 2-3x ULN)

**Key Point:** **Monospot (heterophile antibody) = first-line** (quick, sensitive after 1st week)

---

**Interpretation of EBV Serology:**

| **VCA-IgM** | **VCA-IgG** | **EBNA IgG** | **Interpretation** |
|-------------|-------------|--------------|---------------------|
| **+** | **+** | **-** | **Acute/recent primary infection** |
| **-** | **+** | **+** | **Past infection** (>6 months ago) |
| **-** | **-** | **-** | **No prior EBV infection** (susceptible) |

**Key Point:** **VCA-IgM+ / EBNA IgG-** = acute primary infection

---

### **Complications:**

**Common:**
- **Splenic rupture** (0.1-0.5% - most serious):
  - **Timing:** 2-3 weeks into illness (when spleen largest)
  - **Presentation:** Sudden LUQ pain, Kehr sign (referred left shoulder pain), hypotension
  - **Avoid contact sports** x 3-4 weeks

**Hematologic:**
- **Hemolytic anemia** (cold agglutinin disease - anti-i antibodies)
- **Thrombocytopenia**

**Neurologic:**
- **Aseptic meningitis, encephalitis** (rare)
- **Guillain-Barré syndrome, Bell palsy**

**Cardiac:**
- **Myocarditis** (rare)

**Upper Airway:**
- **Airway obstruction** (tonsillar hypertrophy)

**Key Point:** **Splenic rupture** = most serious complication (avoid contact sports x 3-4 weeks)

---

### **Treatment:**

**Supportive Care (Mainstay):**
- **Rest, hydration, NSAIDs** (fever, pain)
- **NO antivirals** (acyclovir/valacyclovir NOT effective for IM)

**Corticosteroids (Specific Indications ONLY):**
- **Impending airway obstruction** (tonsillar hypertrophy)
- **Severe hemolytic anemia, thrombocytopenia**
- **Neurologic complications** (encephalitis, GBS)

**Regimen:**
- **Prednisone** 1 mg/kg/day (max 60-80 mg) x 5-7 days, then taper

**Key Point:** **Corticosteroids ONLY for specific complications** (NOT routine)

---

**Return to Activity:**
- **Avoid contact sports x 3-4 weeks** (or until splenomegaly resolved)

---

## 2. EBV-ASSOCIATED MALIGNANCIES

---

### **A. Burkitt Lymphoma:**

**Epidemiology:**
- **Endemic (Africa):** EBV+ (95%), associated with malaria
- **Sporadic (US/Europe):** EBV+ (15-20%)

**Clinical Features:**
- **Rapidly growing abdominal mass** (ileocecal region)
- **Jaw mass** (endemic - children in Africa)
- **"Starry sky" appearance** (histology - macrophages among tumor cells)

**Treatment:**
- **Intensive chemotherapy** (CODOX-M/IVAC or similar regimens)
- **Rituximab** (anti-CD20)

**Prognosis:**
- **Highly curable** if treated early (70-90% cure rate)

---

### **B. Hodgkin Lymphoma:**

**EBV Association:**
- **40-50% of Hodgkin lymphoma** (especially mixed cellularity subtype)
- **Reed-Sternberg cells** (EBV+)

---

### **C. Nasopharyngeal Carcinoma:**

**Epidemiology:**
- **Endemic:** Southern China, Southeast Asia
- **EBV+ in >95%**

**Clinical Features:**
- **Neck mass** (cervical lymphadenopathy)
- **Nasal obstruction, epistaxis**
- **Cranial nerve palsies** (advanced)

**Treatment:**
- **Radiation + chemotherapy**

---

### **D. Post-Transplant Lymphoproliferative Disorder (PTLD):**

**Definition:**
- **EBV-driven B-cell lymphoproliferation** post-transplant (uncontrolled proliferation due to immunosuppression)

**Risk Factors:**
- **EBV D+ / R-** (highest risk - primary infection post-transplant)
- **Heavy immunosuppression** (tacrolimus, mycophenolate, anti-T-cell antibodies)
- **Pediatric recipients** (EBV-seronegative)

**Timing:**
- **Early (<1 year):** EBV-driven (polymorphic)
- **Late (>1 year):** Often EBV-negative (monomorphic)

---

**Classification:**

| **Type** | **Features** |
|----------|--------------|
| **Nondestructive PTLD** | IM-like, plasmacytic hyperplasia |
| **Polymorphic PTLD** | Mixture of B-cell types (polymorphic infiltrate) |
| **Monomorphic PTLD** | **DLBCL** (most common), Burkitt lymphoma, plasmablastic lymphoma |
| **Hodgkin lymphoma PTLD** | Classic HL |

**Key Point:** **Monomorphic PTLD = DLBCL** (most common)

---

**Clinical Features:**
- **Fever, lymphadenopathy**
- **B symptoms** (fever, night sweats, weight loss)
- **Organ involvement** (GI, lung, CNS, allograft)

**Diagnosis:**
- **EBV PCR (blood):** Elevated viral load (monitor)
- **Tissue biopsy:** Histology + EBV EBER in situ hybridization

---

**Treatment:**

**Risk-Stratified Approach:**

**Step 1: Reduce Immunosuppression (RIS):**
- **Decrease/hold tacrolimus, mycophenolate**
- **Response:** 20-30% (nondestructive/polymorphic PTLD)

**Step 2: Rituximab (Anti-CD20):**
- **Rituximab** 375 mg/m² IV weekly x 4 doses
- **Response:** 40-60%

**Step 3: Chemotherapy (If Refractory):**
- **R-CHOP** (rituximab + CHOP chemotherapy)

**Additional Options:**
- **EBV-specific cytotoxic T-cells** (CTLs) - investigational
- **Surgical resection** (localized disease)
- **Radiotherapy** (localized CNS PTLD)

**Key Point:** **RIS → Rituximab → Chemotherapy** (stepwise approach)

---

### **E. Oral Hairy Leukoplakia (OHL):**

**Epidemiology:**
- **HIV/AIDS** (CD4 <200)

**Clinical Features:**
- **White, corrugated ("hairy") plaques** on **lateral tongue**
- **Cannot be scraped off** (vs oral candidiasis)
- **Asymptomatic**

**Diagnosis:**
- **Clinical appearance**
- **Biopsy:** EBV DNA (if unclear)

**Treatment:**
- **ART** (resolves with immune reconstitution)
- **Antivirals** (acyclovir, valacyclovir) if symptomatic (NOT usually needed)

**Key Point:** **White "hairy" plaques on lateral tongue** = oral hairy leukoplakia (EBV)

---

### **F. EBV-Associated Hemophagocytic Lymphohistiocytosis (HLH):**

**Definition:**
- **Hyperinflammatory syndrome** (uncontrolled immune activation)

**Triggers:**
- **Primary EBV infection** (especially in Asian populations - genetic predisposition)

**Clinical Features:**
- **Fever, hepatosplenomegaly**
- **Cytopenias** (anemia, thrombocytopenia, neutropenia)
- **Hypertriglyceridemia, hypofibrinogenemia**
- **Hemophagocytosis** (bone marrow)

**Diagnosis (HLH-2004 Criteria):**
- **≥5 of 8 criteria:**
  - Fever, splenomegaly, cytopenias (≥2 lineages)
  - Hypertriglyceridemia (≥265 mg/dL) or hypofibrinogenemia (≤150 mg/dL)
  - Hemophagocytosis (bone marrow, spleen, lymph node)
  - ↓ NK cell activity
  - Ferritin ≥500 μg/L
  - Soluble CD25 (IL-2 receptor) ≥2400 U/mL

**Treatment:**
- **HLH-94 protocol:** Etoposide + dexamethasone (± cyclosporine)
- **HSCT** (if familial HLH)

**Key Point:** **EBV-HLH** = hyperinflammatory syndrome (high ferritin, cytopenias, hemophagocytosis)

---

## COMPARISON TABLE

| **Condition** | **Population** | **Key Clinical Feature** | **Treatment** |
|---------------|----------------|--------------------------|---------------|
| **Infectious mononucleosis** | Adolescents/young adults | **Fever, pharyngitis, lymphadenopathy** | **Supportive** (avoid ampicillin, contact sports x 3-4 weeks) |
| **Burkitt lymphoma** | Children (Africa), adults | **Rapidly growing abdominal/jaw mass** | Intensive chemotherapy + rituximab |
| **PTLD** | Transplant recipients | **Lymphadenopathy, B symptoms** | **RIS → Rituximab → Chemotherapy** |
| **Oral hairy leukoplakia** | HIV (CD4 <200) | **White "hairy" plaques on lateral tongue** | **ART** |
| **EBV-HLH** | Primary EBV infection (Asian) | **Fever, hepatosplenomegaly, cytopenias, ↑↑ ferritin** | Etoposide + dexamethasone |

---

**Mnemonic: "Mono = Monospot (Heterophile Antibody Test)"**
- **M**ono
- **M**onospot = first-line test
- Heterophile antibody

**Mnemonic: "Avoid Ampicillin in Mono (Causes Rash)"**
- **A**void ampicillin/amoxicillin
- **M**ono
- **R**ash (80-100%)

**Mnemonic: "PTLD Treatment = RIS-R-CHOP (Stepwise)"**
- **R**educe immunosuppression (RIS)
- **R**ituximab
- **C**hemotherapy (R-CHOP if refractory)

**Clinical Pearls:**
- **Infectious mononucleosis = fever + pharyngitis + lymphadenopathy** (adolescents/young adults)
- **Monospot (heterophile antibody) = first-line test** (after 1st week)
- **VCA-IgM+ / EBNA IgG-** = acute primary EBV infection
- **Avoid ampicillin/amoxicillin** (causes diffuse rash in 80-100% with IM)
- **Splenic rupture = most serious complication** (avoid contact sports x 3-4 weeks)
- **Corticosteroids ONLY for specific complications** (airway obstruction, severe cytopenias)
- **Burkitt lymphoma:** "Starry sky" histology, highly curable with chemotherapy
- **PTLD = EBV-driven lymphoproliferation** post-transplant
- **Monomorphic PTLD = DLBCL** (most common type)
- **PTLD treatment:** RIS → Rituximab → Chemotherapy (stepwise)
- **Oral hairy leukoplakia** = white "hairy" plaques on lateral tongue (HIV, CD4 <200)
- **EBV-HLH** = hyperinflammatory syndrome (high ferritin, cytopenias, hemophagocytosis)

**Media:** None

**Sources:** [CDC 2024 - Infectious mononucleosis], [NEJM 2024 - EBV-associated malignancies], [Bone Marrow Transplantation 2024 - PTLD treatment update], [Nature 2024 - PTLD pathogenesis], [StatPearls 2024 - Infectious mononucleosis, PTLD]
